Caseware UK (AP4) 2023.0.135 2023.0.135 2024-06-302024-06-30No description of principal activity2023-07-01falsetrue00falsefalse SC694857 2023-07-01 2024-06-30 SC694857 2022-07-01 2023-06-30 SC694857 2024-06-30 SC694857 2023-06-30 SC694857 c:Director1 2023-07-01 2024-06-30 SC694857 c:Director2 2023-07-01 2024-06-30 SC694857 c:RegisteredOffice 2023-07-01 2024-06-30 SC694857 d:CurrentFinancialInstruments 2024-06-30 SC694857 d:CurrentFinancialInstruments 2023-06-30 SC694857 d:ShareCapital 2024-06-30 SC694857 d:ShareCapital 2023-06-30 SC694857 c:OrdinaryShareClass1 2023-07-01 2024-06-30 SC694857 c:OrdinaryShareClass1 2024-06-30 SC694857 c:OrdinaryShareClass1 2023-06-30 SC694857 c:EntityHasNeverTraded 2023-07-01 2024-06-30 SC694857 c:FRS102 2023-07-01 2024-06-30 SC694857 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 SC694857 c:FullAccounts 2023-07-01 2024-06-30 SC694857 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 SC694857 e:PoundSterling 2023-07-01 2024-06-30 xbrli:shares iso4217:GBP xbrli:pure
Registered number: SC694857










ILASCO (MEDICAL) LIMITED
DIRECTORS' REPORT AND FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024

 
ILASCO (MEDICAL) LIMITED
 

COMPANY INFORMATION


Directors
Ms S C Fernando 
Mr S R Fernando 




Registered number
SC694857



Registered office
52-53 Nasmyth Road

Glenrothes

Fife

KY6 2SD




Accountants
EQ Accountants Limited
Chartered Accountants

Pentland House

Saltire Centre

Glenrothes

Fife

KY6 2AH





 
ILASCO (MEDICAL) LIMITED
 

CONTENTS



Page
Directors' report
 
 
1
Statement of financial position
 
 
2
Notes to the financial statements
 
 
3


 
ILASCO (MEDICAL) LIMITED
 

 
DIRECTORS' REPORT
FOR THE PERIOD ENDED 30 JUNE 2024

The directors present their report and the financial statements for the period ended 30 June 2024.

Directors

The directors who served during the period were:

Ms S C Fernando 
Mr S R Fernando 

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.


This report was approved by the board on 31 October 2024 and signed on its behalf.
 





Mr S R Fernando
Director

Page 1

 
ILASCO (MEDICAL) LIMITED
REGISTERED NUMBER: SC694857

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 3 
2
2

  
2
2

Total assets less current liabilities
  
 
 
2
 
 
2

  

Net assets
  
2
2


Capital and reserves
  

Called up share capital 
 4 
2
2

  
2
2


For the period ended 30 June 2024 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 31 October 2024.




Mr S R Fernando
Director

The notes on page 3 form part of these financial statements.

Page 2

 
ILASCO (MEDICAL) LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30 JUNE 2024

1.


General information

Ilasco (Medical) Limited ia a private company, limited by shares and incorporated in Scotland with registration number SC694857. The registered office address is 52 - 53 Nasmyth Road, Southfield Industrial Estate, Glenrothes, Fife, KY6 2SD.
The Company did not trade in the period.
The financial statements are presented in Sterling which is the functional currency of the Company and
rounded to the nearest £. 

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.


3.


Debtors

2024
£


Other debtors
2



4.


Share capital

2024
2023
£
£
Allotted, called up and fully paid



2 (2023 - 2) Ordinary shares of £1.00 each
2
2



5.


Profit and loss account

The Company did not trade during the year and has made neither a profit or a loss. No profit and loss account has therefore been prepared.

Page 3